USP9X inhibition promotes radiation-induced apoptosis in non-small cell lung cancer cells expressing mid-to-high MCL1

References

• Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al. SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.
   Google Scholar
• Scarpaci A, Mitra P, Jarrar D, Masters GA. Multimodality approach to management of stage III non-small cell lung cancer. Surg Oncol Clin N Am 2013; 22:319-28; PMID:23453337; http://dx.doi.org/10.1016/j.soc.2012.12.014
   PubMed Web of Science ®Google Scholar
• Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch A, Bentzen SM, Nam J, Deasy JO. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 2010; 76:S10-9; PMID:20171502; http://dx.doi.org/10.1016/j.ijrobp.2009.07.1754
   PubMed Web of Science ®Google Scholar
• Werner-Wasik M, Yu X, Marks LB, Schultheiss TE. Normal-tissue toxicities of thoracic radiation therapy: esophagus, lung, and spinal cord as organs at risk. Hematol Oncol Clin North Am 2004; 18:131-60, x-xi; PMID:15005286; http://dx.doi.org/10.1016/S0889-8588(03)00150-3
   PubMed Web of Science ®Google Scholar
• Ganem G, Cartron G, Girinsky T, Haas RL, Cosset JM, Solal-Celigny P. Localized low-dose radiotherapy for follicular lymphoma: history, clinical results, mechanisms of action, and future outlooks. Int J Radiat Oncol Biol Phys 2010; 78:975-82; PMID:20970029; http://dx.doi.org/10.1016/j.ijrobp.2010.06.056
   PubMed Web of Science ®Google Scholar
• Stuschke M, Sak A, Wurm R, Sinn B, Wolf G, Stuben G, Budach V. Radiation-induced apoptosis in human non-small-cell lung cancer cell lines is secondary to cell-cycle progression beyond the G2-phase checkpoint. Int J Radiat Biol 2002; 78:807-19; PMID:12428922; http://dx.doi.org/10.1080/09553000210148903
   PubMed Web of Science ®Google Scholar
• Lim KH, Baek KH. Deubiquitinating enzymes as therapeutic targets in cancer. Curr Pharm Des 2013; 19:4039-52; PMID:23181570; http://dx.doi.org/10.2174/1381612811319220013
   PubMed Web of Science ®Google Scholar
• Eletr ZM, Wilkinson KD. Regulation of proteolysis by human deubiquitinating enzymes. Biochim Biophys Acta 2014; 1843:114-28; PMID:23845989; http://dx.doi.org/10.1016/j.bbamcr.2013.06.027
   PubMed Web of Science ®Google Scholar
• Schwickart M, Huang X, Lill JR, Liu J, Ferrando R, French DM, Maecker H, O'Rourke K, Bazan F, Eastham-Anderson J, et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 2010; 463:103-7; PMID:20023629; http://dx.doi.org/10.1038/nature08646
   PubMed Web of Science ®Google Scholar
• Trivigno D, Essmann F, Huber SM, Rudner J. Deubiquitinase USP9x confers radioresistance through stabilization of Mcl-1. Neoplasia 2012; 14:893-904; PMID:23097624
   PubMed Web of Science ®Google Scholar
• Kapuria V, Peterson LF, Fang D, Bornmann WG, Talpaz M, Donato NJ. Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Res 2010; 70:9265-76; PMID:21045142; http://dx.doi.org/10.1158/0008-5472.CAN-10-1530
   PubMed Web of Science ®Google Scholar
• Pal A, Young MA, Donato NJ. Emerging potential of therapeutic targeting of ubiquitin-specific proteases in the treatment of cancer. Cancer Res 2014; 74:4955-66; PMID:25172841; http://dx.doi.org/10.1158/0008-5472.CAN-14-1211
   PubMed Web of Science ®Google Scholar
• Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483:603-7; PMID:22460905; http://dx.doi.org/10.1038/nature11003
   PubMed Web of Science ®Google Scholar
• Chen Z, Cheng K, Walton Z, Wang Y, Ebi H, Shimamura T, Liu Y, Tupper T, Ouyang J, Li J, et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 2012; 483:613-7; PMID:22425996; http://dx.doi.org/10.1038/nature10937
   PubMed Web of Science ®Google Scholar
• Hanel W, Moll UM. Links between mutant p53 and genomic instability. J Cell Biochem 2012; 113:433-9; PMID:22006292; http://dx.doi.org/10.1002/jcb.23400
   PubMed Web of Science ®Google Scholar
• Li J, Zhu S, Kozono D, Ng K, Futalan D, Shen Y, Akers JC, Steed T, Kushwaha D, Schlabach M, et al. Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma. Oncotarget 2014; 5:882-93; PMID:24658464
   PubMedGoogle Scholar
• Sigoillot FD, King RW. Vigilance and validation: Keys to success in RNAi screening. ACS Chem Biol 2011; 6:47-60; PMID:21142076; http://dx.doi.org/10.1021/cb100358f
   PubMed Web of Science ®Google Scholar
• Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S, Wang HG, Zhang X, Bullrich F, Croce CM, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. Blood 1998; 91:3379-89; PMID:9558396
   PubMed Web of Science ®Google Scholar
• Lestini BJ, Goldsmith KC, Fluchel MN, Liu X, Chen NL, Goyal B, Pawel BR, Hogarty MD. Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists. Cancer Biol Ther 2009; 8:1587-95; PMID:19556859; http://dx.doi.org/10.4161/cbt.8.16.8964
   PubMed Web of Science ®Google Scholar
• Billard C. BH3 mimetics: status of the field and new developments. Mol Cancer Ther 2013; 12:1691-700; PMID:23974697; http://dx.doi.org/10.1158/1535-7163.MCT-13-0058
   PubMed Web of Science ®Google Scholar
• Perez-Mancera PA, Rust AG, van der Weyden L, Kristiansen G, Li A, Sarver AL, Silverstein KA, Grützmann R, Aust D, Rümmele P, et al. The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature 2012; 486:266-70; PMID:22699621
   PubMed Web of Science ®Google Scholar
• Cox JL, Wilder PJ, Wuebben EL, Ouellette MM, Hollingsworth MA, Rizzino A. Context-dependent function of the deubiquitinating enzyme USP9X in pancreatic ductal adenocarcinoma. Cancer Biol Ther 2014; 15:1042-52; PMID:24841553; http://dx.doi.org/10.4161/cbt.29182
   PubMed Web of Science ®Google Scholar
• Yan J, Zhong N, Liu G, Chen K, Liu X, Su L, Singhal S. Usp9x- and Noxa-mediated Mcl-1 downregulation contributes to pemetrexed-induced apoptosis in human non-small-cell lung cancer cells. Cell Death Dis 2014; 5:e1316; PMID:24991768; http://dx.doi.org/10.1038/cddis.2014.281
   PubMed Web of Science ®Google Scholar
• Dupont S, Mamidi A, Cordenonsi M, Montagner M, Zacchigna L, Adorno M, Martello G, Stinchfield MJ, Soligo S, Morsut L, et al. FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination. Cell 2009; 136:123-35; PMID:19135894; http://dx.doi.org/10.1016/j.cell.2008.10.051
   PubMed Web of Science ®Google Scholar
• Xie Y, Avello M, Schirle M, McWhinnie E, Feng Y, Bric-Furlong E, Wilson C, Nathans R, Zhang J, Kirschner MW, et al. Deubiquitinase FAM/USP9X interacts with the E3 ubiquitin ligase SMURF1 protein and protects it from ligase activity-dependent self-degradation. J Biol Chem 2013; 288:2976-85; PMID:23184937; http://dx.doi.org/10.1074/jbc.M112.430066
   PubMed Web of Science ®Google Scholar
• Hao L, He Q, Wang Z, Craven M, Newton MA, Ahlquist P. Limited agreement of independent RNAi screens for virus-required host genes owes more to false-negative than false-positive factors. PLoS Comp Biol 2013; 9:e1003235; PMID:24068911; http://dx.doi.org/10.1371/journal.pcbi.1003235
   PubMedGoogle Scholar